Principal Investigator: Dr. John O?Mahony
Dr. Sean Peterson
Dr. Michael O?Mahony
Dr. Sean Peterson
Dr. Michael O?Mahony
Study Coordinator(s): Laura Croft
Maria Michelin
Suzy Webster
Teresa Ferrari-Nicefield
Shirley John
Amanda Leystra
Hannah Miles
Lacy Manettas
Maria Michelin
Suzy Webster
Teresa Ferrari-Nicefield
Shirley John
Amanda Leystra
Hannah Miles
Lacy Manettas
Facility Name: Bluewater Clinical Research Group
Website: http://www.bwresearch.ca/
Clinic Hours: Monday - Friday: 8AM - 4PM
Saturday - Sunday: Closed
Saturday - Sunday: Closed
Bluewater Clinical Research Group has it's origins with three local Family Physicians. Doctors Michael O'Mahony, John O'Mahony and Sean Peterson are dedicated family medicine practitioners, who are also engaged in advancing medical knowledge and medical care by conducting both ethical and high-quality clinical studies. By partnering with Sarnia-Lambton residents, physicians and nurse practitioners, we are able to direct leading-edge clinical research.
Research Site Location: 481 London Road - Lower Level Suite, Sarnia, ON, N7T 4X3
481 London Road - Lower Level Suite
481 London Road - Lower Level Suite, Sarnia, ON, N7T 4X3
View larger mapCurrent Research Studies:
- E. Coli Vaccine Research Study
- Retatrutide Study for Obesity or Overweight
- Chronic Migraine Prevention Research
- Episodic Migraine Prevention Study in Adults
- Cardiovascular Safety in People With Obesity (SYNCHRONIZE™ – CVOT)
- Cardiovascular Risk and Hypertension Study of Zilebesiran
- Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities
- Study of Chronic Neuropathic Pain Associated with Distal Sensory Polyneuropathy (DSP)
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia (SHASTA-3)
- Study of Plozasiran in Adults With Hypertriglyceridemia (MUIR-3)
- Study for Participants Living with Obesity, or Overweight with Comorbidity
- Study for Adults With Type 2 Diabetes Mellitus
- Influenza Vaccine Study in Adults ≥50 Years of Age
- Norovirus mRNA Vaccine Research Study
- Étude sur le zilbesiran, le risque cardiovasculaire et l’hypertension
Research Experience:
